Sepsis and septic shock have been notoriously difficult indications for drug development. However, considering the high incidence of sepsis,...
The growing number of postmenopausal women translates into new challenges for clinicians as they strive to help women stay healthy during the...
All eyes have been on the first selective COX-2 inhibitors, celecoxib (Pharmacia and Pfizer's Celebrex) and rofecoxib (Merck's Vioxx), for the...
Decision Resources, Inc., announces the publication of Type 2 Diabetes, a new study that evaluates the commercial potential of novel agents to...
Decision Resources, Inc., a pharmaceutical research and consulting firm, is pleased to announce the election of two new Vice Presidents-James...
Using Clinical Trials to Strategic Advantage is a new DR Report from Decision Resources, Inc., that explains how clinical trials can be invaluable...
Post-Myocardial Infarction is a new study from Decision Resources, Inc., that examines how the need for better and novel cardioprotective agents to...
Asthma is a new Decision Resources study that examines novel drug development efforts arising from a wealth of research into the pathophysiology of...